MIDAS

Safety Shot’s Jupiter Wellness Legacy Assets Licensed to Elite Health Partners: Safety Shot to Dividend 40% of Post-IPO Wellness Powerhouse To Its Shareholders

Retrieved on: 
Thursday, February 22, 2024

All Safety Shot beverage assets remain with Safety Shot Inc.

Key Points: 
  • All Safety Shot beverage assets remain with Safety Shot Inc.
    JUPITER, FL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced it has signed an agreement to license and sell its legacy Jupiter Wellness assets to Colorado-based Elite Health Partners Inc.
  • The Company’s Jupiter Wellness assets include a portfolio of over-the-counter commercialized products as well as product candidates in development for indications including skin care, hair growth, and women’s health.
  • Elite Health is a leading provider of world-class, innovative products and services that fulfill a broad range of consumer health and beauty needs globally.
  • We are very pleased to partner with Safety Shot and believe our joint assets and the future potential of Elite Health.”

Generational Equity Advises Reed Automotive Service in its asset sale to a Private Investment Group

Retrieved on: 
Wednesday, February 14, 2024

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the asset sale of its client, Reed Automotive Service, Inc. to a Private Investment Group.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the asset sale of its client, Reed Automotive Service, Inc. to a Private Investment Group.
  • Founded in 2011, Reed Automotive Service, Inc. (RAS), located in Indianapolis, Indiana, is a holding company of three MIDAS franchises that are premium providers of tire, automotive, and other related services and sales.
  • Over the past 12 years, RAS has developed a vast database of loyal and long-term clients backed by the MIDAS brand.
  • Generational Equity Executive Managing Director of M&A – Central Region, Michael Goss , Tom Poyser, a Generational Group Authorized Affiliate, with the support of Vice President, Madison Buckley successfully closed the transaction.

Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos’ POD® Appliance Treatment

Retrieved on: 
Monday, May 1, 2023

The study demonstrated statistically significant results, with ninety-two percent (92%) of study patients reporting their migraine symptoms were completely resolved following completion of treatment.

Key Points: 
  • The study demonstrated statistically significant results, with ninety-two percent (92%) of study patients reporting their migraine symptoms were completely resolved following completion of treatment.
  • Prior to treatment patients had an average MIDAS score of 23.96 +/- 21.34 and following treatment had a MIDAS score of 2.58 +/- 4.87, a reduction of 89.2%.
  • Migraine headaches affect over 39 million people in the United States alone according to the American Migraine Foundation.
  • Dentists who are using this technology report migraine resolution in about 9 out of 10 migraine sufferers.

Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform

Retrieved on: 
Monday, March 13, 2023

These highly conserved protein-metabolite interactions hold vast disease-relevant and therapeutically actionable information; however, they are frequently low affinity and have historically proven challenging to systematically discover.

Key Points: 
  • These highly conserved protein-metabolite interactions hold vast disease-relevant and therapeutically actionable information; however, they are frequently low affinity and have historically proven challenging to systematically discover.
  • The Science paper, entitled, “Protein-metabolite interactomics of carbohydrate metabolism reveal regulation of lactate dehydrogenase,” (Hicks et al.)
  • Together with postdoctoral fellow, Kevin Hicks, Ph.D., Dr. Rutter, Distinguished Professor of Biochemistry and HHMI Investigator at the University of Utah, developed the MIDAS technology.
  • The powerful insights described in the Science paper present just an initial understanding of this technology’s ultimate potential.

Aspen Surgical Acquires Symmetry Surgical

Retrieved on: 
Thursday, October 27, 2022

Aspen Surgical Products, Inc. (Aspen), a portfolio company of Audax Private Equity (Audax) and a leader in disposable surgical products, announced the acquisition of Symmetry Surgical (Symmetry) from RoundTable Healthcare Partners.

Key Points: 
  • Aspen Surgical Products, Inc. (Aspen), a portfolio company of Audax Private Equity (Audax) and a leader in disposable surgical products, announced the acquisition of Symmetry Surgical (Symmetry) from RoundTable Healthcare Partners.
  • There is great power in bringing the people, products, and brands of Aspen and Symmetry together, added Brian Straeb, CEO of Symmetry.
  • Symmetry Surgical is a leading healthcare technology and solutions supplier of high-quality surgical instrumentation, a full-line electrosurgery portfolio, and minimally invasive surgical devices that support all surgical specialties and sites of care.
  • Wherever surgeries are performed, surgical teams can trust that Symmetry Surgical instruments and devices will operate efficiently and safely.

Team V-BAT - A Proven Tactical UAS Solution for RCN ISTAR

Retrieved on: 
Tuesday, October 4, 2022

The V-BAT can carry multiple ISR sensor payloads simultaneously to provide a variety of tactical mission capabilities over land and at sea.

Key Points: 
  • The V-BAT can carry multiple ISR sensor payloads simultaneously to provide a variety of tactical mission capabilities over land and at sea.
  • Together Voyageur Aviation, Shield.AI and Kongsberg Geospatial (Team V-BAT) will offer the Royal Canadian Navy a high-performing and proven UAS supported by Canadian partners for both domestic and global operations.
  • Please see Team V-Bat and the aircraft at DEFSEC (Halifax) on Oct 5 - 6th 2022 in booth P109-110.
  • www.voyav.com
    Shield AI is a venture-backed company built around a team of proven executives, warfighters with relevant national security experience, and world-class AI engineers.

North Highland Goes North With Second UK Office Location

Retrieved on: 
Monday, July 11, 2022

ATLANTA, July 11, 2022 /PRNewswire/ -- North Highland , the leading change and transformation consultancy, has expanded its UK presence with a new office in the city centre of Manchester, England.

Key Points: 
  • ATLANTA, July 11, 2022 /PRNewswire/ -- North Highland , the leading change and transformation consultancy, has expanded its UK presence with a new office in the city centre of Manchester, England.
  • Named by Forbes as a best consulting firm to work for, North Highland is expected to create more than 100 jobs with the move.
  • North Highland's first UK office in London has been around since 2003.
  • North Highland is currently recruiting for talent to join the team at its new Manchester office.

North Highland Goes North With Second UK Office Location

Retrieved on: 
Monday, July 11, 2022

ATLANTA, July 11, 2022 /PRNewswire/ -- North Highland , the leading change and transformation consultancy, has expanded its UK presence with a new office in the city centre of Manchester, England.

Key Points: 
  • ATLANTA, July 11, 2022 /PRNewswire/ -- North Highland , the leading change and transformation consultancy, has expanded its UK presence with a new office in the city centre of Manchester, England.
  • Named by Forbes as a best consulting firm to work for, North Highland is expected to create more than 100 jobs with the move.
  • North Highland's first UK office in London has been around since 2003.
  • North Highland is currently recruiting for talent to join the team at its new Manchester office.

Canadian Coast Guard Conducts Offshore Sea Trials of VTOL UAS with Shield AI and Kongsberg Geospatial

Retrieved on: 
Wednesday, January 26, 2022

The Canadian Coast Guard is conducting trials of the long-endurance Vertical Take-of and Landing (VTOL) UAS surveillance system for possible deployment on Canadian Coast Guard Vessels under a project funded by Defence Research and Development Canada (DRDC).

Key Points: 
  • The Canadian Coast Guard is conducting trials of the long-endurance Vertical Take-of and Landing (VTOL) UAS surveillance system for possible deployment on Canadian Coast Guard Vessels under a project funded by Defence Research and Development Canada (DRDC).
  • Kongsberg Geospatial teamed with Shield AI to deploy the V-BAT VTOL UAS for a 3-day sea trial in international waters in the Gulf of Mexico.
  • This series of endurance trials is the second set of flight trials of the Shield AI V-BAT conducted by the Canadian Coast Guard.
  • For more information visit: Shield.AI
    About the Canadian Coast Guard: Headquartered in Ottawa, the Canadian Coast Guard ( https://www.ccg-gcc.gc.ca/index-eng.html ) is the coast guard of Canada.

From Clinical Trial Efficacy to Real-World Effectiveness First AJOVY® ▼ (fremanezumab) Data from European Real World Evidence Program

Retrieved on: 
Monday, November 8, 2021

Real-world evidence can provide vital insight into treatment effects in more naturalistic clinical settings, where many patients have multiple co-morbidities, said Professor Straube.

Key Points: 
  • Real-world evidence can provide vital insight into treatment effects in more naturalistic clinical settings, where many patients have multiple co-morbidities, said Professor Straube.
  • 48.7% of the patients with 6-month data achieved the primary endpoint, with a higher percentage in EM (53.2%) than CM patients (43.0%).
  • Danilo Lembo, Vice President Teva Medical Affairs EU commented:
    To provide further support in understanding migraine prevention in clinical practice, we have initiated a comprehensive European Real World Evidence program with FINESSE and PEARL studies which are being carried out throughout Europe.
  • Also real-world evidence is complementary to randomized clinical trial and in recent years it has become increasingly important to improve clinical practice, amend treatment guidelines and support access decisions.